GHP Funds


SVP I, the debut fund for the firm, closed in December 2002 and invested with four highly successful leveraged buyout funds. SVP I is diversified by sector and geography.

Learn More

SVP II is a leveraged buyout fund of funds which closed in December 2006. SVP II represents a continuation of the successful strategy utilized by the predecessor fund, primarily investing with large, top tier LBO and growth equity firms. SVP II is diversified by sector and geography.

Learn More

SVP Real Estate I, LP ("SVP RE I"), closed in February 2008, is a private real estate fund of funds. As with SVP I & II, SVP RE I received allocations with historically successful, highly sought after underlying fund managers who pursue compelling investment strategies. The fund is diversified by sector (Office, Hotel, Industrial/Warehouse, Retail and Residential) and geography (U.S., Europe, and Asia/Pacific).

Learn More

The GHP Credit Opportunity Fund (“GHP COF”) is a fund of alternative credit and distressed debt funds that is being raised and invested to pursue two specific investment themes: (1) the de-leveraging of European Banks, and (2) the potential for a distressed cycle in U.S. High Yield Credit. GHP COF will pursue complex liquid and illiquid credit opportunities in the U.S. and Europe.

Learn More

GHP Library

Sunniva Inc. Announces Cannabis Telehealth Service Agreement Between Natural Health Services Ltd and HelloMD to Expand Patient Reach With Enhanced Medical Cannabis Services in Canada

VANCOUVER, British Columbia and TORONTO, Dec. 18, 2018 (GLOBE NEWSWIRE) — Sunniva Inc. (“Sunniva”, the “Company”, “we”, “our” or “us”) (CSE:SNN) (OTCQB:SNNVF), a North American provider of cannabis products and services, announced today that its wholly owned subsidiary,  Natural Health Services Ltd. (“NHS”), will partner with HelloMD, a leading online cannabis telehealth company, to offer telemedicine services to its patients to provide more Canadian communities with convenient access to medical cannabis advice.

NHS operates a network of seven clinics specializing in medical cannabis in four provinces and has approximately 105,000 registered patients. In this joint effort, HelloMD will provide its turnkey set of white-label services to NHS, affording existing and future NHS patients the added option and convenience of an online health care practitioner consultation. In addition, NHS will have the opportunity to extend its services to areas where they do not currently have clinics, to reduce wait times, and to offer the convenience of evening and weekend consultations.

“This partnership is about both companies focusing on what they do best,” said Larry Lisser, HelloMD’s SVP of Business Development. “HelloMD’s telehealth service extends access to practitioner-led advice to more Canadians, while our integration with the NHS platform enables their patients to seamlessly benefit from the educational services NHS is so well known for. This is a win for patients all around.”

NHS patients will be first directed to a co-branded landing page on the HelloMD platform. Those patients who receive a medical document from HelloMD will be seamlessly transferred to an NHS Patient Educator who in turn helps them to understand the various options available and assists them in the selection of a Licensed Producer from which to buy medical cannabis.

Dr. Mark Kimmins, Medical Director and Interim President of NHS commented, “Partnering with HelloMD enhances the NHS mission to improve the way Canadians access safe, regulated medical cannabis and education on how to use cannabis to improve health and quality of life. By utilizing the telehealth expertise of HelloMD, we will be able to increase our patient base and serve the needs of more Canadians.”

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

About HelloMD: 
HelloMD has facilitated more than 100,000 virtual consults between medical cannabis patients and licensed practitioners. The company’s white-label solutions enable third parties to quickly deploy a turnkey telehealth solution, complete with the technology, practitioners and support personnel required to improve their own patient onboarding processes.

For further information about HelloMD:

Leave a Comment